Treatment of such diseases in adults as: cryptococcal meningitis; coccidioidomycosis; invasive candidiasis; candidiasis of the mucous membranes, including candidiasis of the oropharynx and candidiasis of the esophagus, candiduria, chronic candidiasis of the skin and mucous membranes; chronic atrophic candidiasis (candidiasis caused by the use of dentures) with the ineffectiveness of local dental hygiene products; vaginal candidiasis, acute or recurrent when topical therapy is inappropriate; candidal balanitis when topical therapy is inappropriate; dermatomycosis, including mycosis of the feet, mycosis of smooth skin, inguinal dermatomycosis; tinea versicolor and candidal skin infections when systemic therapy is inappropriate; dermatophytic onychomycosis, when the use of other drugs is inappropriate. Prevention of such diseases in adults as: relapse of cryptococcal meningitis in patients at high risk of its development; recurrence of oropharyngeal or esophageal candidiasis in HIV-infected patients with a high risk of its development; a decrease in the frequency of relapses of vaginal candidiasis (4 or more cases per year); prevention of candidal infections in patients with long-term neutropenia (for example, patients with malignant blood diseases receiving chemotherapy or patients with hematopoietic stem cell transplantation). Children: the drug can be used in children over 5 years of age. The drug is used in children for the treatment of mucosal candidiasis (oropharyngeal candidiasis, esophageal candidiasis), invasive candidiasis, cryptococcal meningitis and for the prevention of candidiasis infections in patients with reduced immunity. The drug can be used as supportive therapy to prevent recurrence of cryptococcal meningitis in children at high risk of developing it. Therapy can be started before the results of cultural and other laboratory studies are obtained; after the results are obtained, antibiotic therapy should be adjusted accordingly.